Black Diamond Therapeutics, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Black Diamond Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
0
70
Research and development
6.95
21.8
48.2
96.8
64.4
59.4
51.3
33.6
General and administrative
1.95
7.58
21.4
30
28.4
27.1
27.5
16.6
Operating expenses
8.9
29.3
69.6
127
92.8
86.5
78.8
57.5
Operating income
-8.9
-29.3
-69.6
-127
-92.8
-86.5
-78.8
12.5
Interest expense
0
0
0
Other non-operating income
-0.03
-5.93
2.32
1.28
3.91
4.02
9.11
9.85
Pre-tax income
-67
-125
-91.3
-82.6
-69.7
22.4
Income tax
0
0
0
0
0
0
0
0
Net income
-8.93
-35.3
-67.3
-126
-91.2
-82.4
-69.7
22.4
EBITDA
-8.86
-29.3
-69.5
-127
-92.3
-86
-78.4
12.8
EPS, basic
-4.42
-16.99
-2.05
-3.47
-2.52
-1.88
-1.27
0.39
EPS, diluted
-4.42
-16.99
-2.05
-3.47
-2.52
-1.88
-1.27
0.39
Shares, basic (weighted)
2.02
2.08
32.9
36.2
36.3
44
55
56.9
Shares, diluted (weighted)
2.02
2.08
32.9
36.2
36.3
44
55
57.6
Balance sheet
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
51.7
155
34.6
65.8
34.3
56.2
36.4
21
Short-term investments
0
280
144
88.5
75.2
62.1
108
Other current assets
0.02
1.05
4.49
5.92
4.9
2.63
2.6
3.79
Total current assets
51.7
156
320
216
128
134
101
132
Property, plant and equipment
0.13
0.16
0.39
3.04
2.59
1.73
1.39
0.37
Lease right-of-use assets
8.4
27.7
24.8
22
19
9.3
Long-term investments
0
Other non-current assets
0.01
0.06
0.11
0.02
0
0
0.25
0.07
Total assets
51.8
158
330
248
156
159
123
143
Accounts payable
0.42
1.96
2.54
4.11
1.88
2.32
4.01
0.58
Accrued liabilities
0.45
2.9
11.7
19.5
13.4
17.3
16.6
15.2
Total current liabilities
2.58
4.86
14.2
23.6
15.3
19.6
20.6
15.7
Lease liabilities
7.69
28.1
25.3
22.2
18.8
15.1
Total liabilities
6.6
4.88
21.9
51.8
40.6
41.8
39.4
30.8
Paid-in capital
0.17
3.81
425
440
453
534
570
577
Retained earnings
-15.7
-51
-118
-244
-335
-417
-487
-465
Other comprehensive income
0
0.61
-0.41
-1.82
-0.03
0.02
0.1
Shareholders' equity
-15.5
-47.2
308
196
116
117
83.3
112
Total equity
-15.5
-47.2
308
196
116
117
83.3
112
Total liabilities and equity
51.8
158
330
248
156
159
123
143
Shares outstanding
2.17
2.24
36.1
36.2
36.4
51.6
56.6
57.1
Cash flow statement
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-8.93
-35.3
-67.3
-126
-91.2
-82.4
-69.7
22.4
Depreciation and amortization
0.04
0.05
0.05
0.21
0.51
0.44
0.34
0.33
Stock-based compensation
0.06
3.64
7.77
14
12.2
9.6
10.6
6.63
Cash from operations
-8.45
-24.7
-52.1
-100
-85.1
-66.7
-62.3
29.6
Capital expenditures
-0.08
-0.02
-0.14
-2.71
-0.19
-0.03
0
Purchases of investments
0
-372
-49.5
-60.1
-61.9
-123
-164
Cash from investing
-0.08
-0.02
-282
131
53.4
16.3
17
-44.9
Stock issued
0
1.1
0.73
0
71.9
24.5
0
Cash from financing
52.3
128
215
0.73
0.18
71.9
25.5
-0.15
Net change in cash
43.8
103
-119
31.2
-31.5
21.6
-19.8
-15.4
Free cash flow
-8.53
-24.7
-52.3
-103
-85.3
-66.8
-62.3
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.88 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-44.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-34.0%
Net income / average total assets.
Return on invested capital (ROIC)
-53.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
34.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-1.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-18.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
16.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-2.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-15.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
4.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
16.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
11.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.28x
Current assets / current liabilities.
Quick ratio
6.98x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.98x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.57
Cash from operations / diluted weighted shares.
Book value per share
$1.67
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.12x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.12x
Market cap / tangible book value, when positive.
Earnings yield
-39.4%
Net income / market cap (the inverse of P/E).
What was Black Diamond Therapeutics, Inc.'s revenue in fiscal 2025?
Black Diamond Therapeutics, Inc. reported revenue of $70.0M for fiscal 2025.
Was Black Diamond Therapeutics, Inc. profitable in fiscal 2025?
Yes. Net income was $22.4M, a net margin of 32%.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.